INTRODUCTION
In Gram-positive pathogens, the cell surface is a complex milieu of proteins that play a pivotal role in adhesion to human tissues, as well as the evasion of host-immune responses [1, 2] . A number of important virulence factors, such as Protein A, fibronectinbinding proteins A and B and collagen-binding protein are covalently attached to the bacterial cell wall by a pathway that is ubiquitous amongst Gram-positive organisms. These proteins are characterized by the presence of a distinctive C-terminal ' sorting sequence ' composed of three different elements : a charged tail, a preceding hydrophobic sequence and a conserved -Leu-Pro-Xaa-Thr-Gly-motif (where Xaa represents any amino acid) [3] [4] [5] . An elegant series of experiments by Schneewind et al. [6] [7] [8] [9] have now characterized the molecular events involved in the presentation of -Leu-Pro-Xaa-Thr-Gly-proteins on the surface of Gram-positive organisms. They identified, cloned and sequenced a cytoplasmic membrane-bound cysteine protease-transpeptidase responsible for the cleavage and covalent linkage of proteins containing the conserved -Leu-Pro-Xaa-Thr-Gly-sequence motif. This constitutively expressed enzyme, known as staphylococcal surface protein sorting A (SrtA), contains a single active-site cysteine residue (Cys")%), which catalyses (via nucleophilic attack) a highly specific cleavage of the scissile Thr-Gly peptide bond in -Leu-Pro-Xaa-Thr-Gly-. The thiol-acyl enzyme intermediate formed between the thiol group of Cys")% and the carbonyl group of Thr is subsequently linked, via an amide bond, to pentaglycine cross-bridges in the bacterial cell wall [10] . Very recently [11] , Schneewind et al. identified a second sortase species (SrtB) in Staphylococcus aureus. This protease, which also appears to employ an active-site cysteine residue for catalysis, has a different subsite specificity from SrtA and cleaves surface proteins at an -Asn-Pro-Gln-Thr-Asn-signal sequence, before anchoring the polypeptide to the cell-wall envelope. The SrtB protease, which is transcribed from an iron-regulated operon, appears dedicated Abbreviations used : Ahx, aminohexanoyl ; BCCP, biotin carboxyl carrier protein ; Cbz, benzyloxycarbonyl ; Dabcyl, 4-([4-(dimethylamino)phenyl]azo)-benzoyl-; Edans, [(2-aminoethyl)-amino]napthalene-1-sulphonyl ; Fmoc, fluoren-9-ylmethoxycarbonyl ; HBTU, 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate ; LB, Luria-Bertani ; Ni-NTA, Ni 2 + -nitrilotriacetate ; SrtA, staphylococcal surface protein sorting A. 1 To whom correspondence should be addressed (e-mail brian.walker!qub.ac.uk).
greater than that determined for the peptidyl-diazomethane (I). Additionally, using Western-blot analysis, we have been able to demonstrate that a biotinylated version of the peptidyldiazomethane analogue, biotin-Ahx (aminohexanoyl)-Leu-ProAla-Thr-CHN # (III), can be used as an affinity label to detect the presence of wild-type SrtA in crude cell lysates prepared from S. aureus.
Key words : biotinylated probe, peptidyl-chloromethane, peptidyl-diazomethane, recombinant, Western blotting.
to the acquisition of iron from the host environment, which is important for the pathogenesis of S. aureus infections.
Biological studies have shown that knockout mutation of the SrtA gene in S. aureus inhibits the organism's adherence to IgG, fibrinogen and fibronectin, and greatly reduces the capacity of the pathogen to establish an acute infection in mice [12] . In addition, inactivation of the SrtA gene in the human commensal bacterium Streptococcus gordonii significantly compromises the ability of the organism to colonize the oral mucosa in mice [13] . Studies with an SrtB mutant strain of S. aureus have revealed no significant reduction in pathogenicity during the early stages of infection in mice [11] . However, over a period of time, the level of infection in the animals injected with the mutant strain was found to decrease significantly when compared with a wild-type strain of S. aureus. This suggests that SrtB does not influence the initial establishment of infection, but is required for persistence of the pathogen within infected tissues. Therefore both SrtA and SrtB are important virulence factors, but they appear to play different roles in the infection process.
It is clear that, in an era of growing antibiotic resistance, both SrtA and SrtB may prove exciting new targets for the development of anti-staphylococcal drugs, or even broad-spectrum agents against Gram-positive pathogens. Against this background, we now describe the first synthesis and kinetic evaluation of substrate-derived inhibitors of SrtA, including a biotinylated version that could prove valuable for the detection and disclosure of novel SrtA-like species (specific for -Leu-Pro-Xaa-Thr-Glymotifs) in extracts from Gram-positive organisms [14] .
EXPERIMENTAL Materials
All protected amino acids, Wang Resin and coupling reagents used for peptide synthesis were purchased from CalbiochemNovabiochem (Nottingham, U.K.). All solvents for peptide Figure 1 Molecular structures of the substrate-derived SrtA ∆N inhibitors Molecular structures correspond to the peptidyl-diazomethane inhibitor Cbz-Leu-Pro-Ala-Thr-CHN 2 (I), the peptidyl-chloromethane inhibitor Cbz-Leu-Pro-Ala-Thr-CH 2 Cl (II) and the biotinpeptidyl-diazomethane inhibitor biotin-Ahx-Leu-Pro-Ala-Thr-CHN 2 (III).
synthesis were obtained from Applied Biosystems (Warrington, Cheshire, U.K.). S. aureus (Oxford strain) was from the A.T.C.C. 9144 (Manassas, VA, U.S.A.). Luria-Bertani (LB) broth was purchased from Oxoid (Basingstoke, U.K.). The pET-3d expression system, and the antibiotics ampicillin and chloramphenicol were purchased from Novagen (Madison, WI, U.S.A.). Ni# + -nitrilotriacetate (Ni-NTA)-agarose was purchased from Qiagen (Crawley, West Sussex, U.K.). Biotin, BSA, the substrates 5-bromo-4-chloroindol-3-yl phosphate and Nitro Blue Tetrazolium, isopropyl β--thiogalactoside and goat anti-rabbit IgG alkaline phosphatase were from Sigma-Aldrich (Poole, Dorset, U.K.). Novex2 SDS\PAGE gels were from Invitrogen (Groningen, The Netherlands), whereas streptavidin-alkaline phosphatase was from Vector Laboratories (Peterborough, U.K.). Rabbit antiserum raised against recombinant sortase SrtA ∆ N was a gift from Fusion Antibodies Ltd. (Belfast, U.K.).
Synthesis of substrate-derived inhibitors
The substrate-derived inhibitor sequences (illustrated in Figure 1 ) were synthesized using a combination of solid-phase and solution methodologies previously reported by our group (Figure 2 ; [15] [16] [17] ). In essence, the -Leu-Pro-Ala-Thr-portion of each inhibitor was synthesized (0.5 mmol scale) using standard solid-phase synthesis protocols on acid-sensitive Wang resin, previously derivatized with fluoren-9-ylmethoxycarbonyl (Fmoc)-Thr-(OBut)-OH as the first amino acid [18] . Each subsequent amino acid was incorporated via single 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU)-mediated couplings. Both alanine and proline residues were incorporated as their N-α-Fmoc derivatives. For inhibitor sequences I and II, the common leucine residue was incorporated as an N-protected benzyloxycarbonyl (Cbz) derivative. For the biotinylated sequence III, the leucine residue was incorporated as an N-α-Fmoc derivative, as was the aminohexanoic linker residue. Biotin was incorporated into the sequence using a double-coupling step. On completion of each synthesis, the peptides were cleaved from the solid support by treatment with a 10 ml solution of 95 % (v\v) trifluoroacetic acid containing 2.5 % (v\v) double-distilled water and 2.5 % (v\v) tri-isopropyl silane. Each cleavage reaction was concentrated to approx. 0.5 ml by evaporation under reduced pressure. The peptide product was then precipitated by dilution (1 : 20) with chilled diethyl ether and isolated by centrifugation (2000 g for 10 min). The products (yields of 80 %) were dried in acuo, for 12 h, before the next stage of the synthesis. The peptides (obtained as their C-terminal free acids) were then activated, via a mixed carbonic anhydride, and converted into their respective diazomethanes by reaction with ethereal diazomethane [15] . The peptidyl-chloromethane inhibitor (II) was prepared (in quantitative yield) by treating a sample (0.1 mmol) of inhibitor I with a 10 ml solution of anhydrous ethereal HCl, for 15 min at 0 mC [19] . The purity and identity of each product was confirmed by reverse-phase HPLC and matrix-assisted laserdesorption ionization-time-of-flight (MALDI-TOF)-MS.
PCR cloning, expression and purification of recombinant SrtA ∆N
SrtA is believed to be a membrane-associated protease, with an N-terminal membrane anchor. To facilitate purification and solubility, a recombinant form of sortase (SrtA ∆ N ) has previously been described and used in which the N-terminal membrane anchor segment of the enzyme (residues 2-25) was replaced with a hexahistidine (His ' ) sequence [8, 9, 12] . In our study, we adopted a similar strategy and created a construct for SrtA ∆ N by replacing the N-terminal T7 tag in a pET-3d expression vector with a His ' tag. The region of the SrtA gene lacking the N-terminal membrane domain was then PCR-amplified from the genomic DNA of S. aureus (Oxford strain) using the primers orf6N-ds-B (5h-AAAGGATCCAAACCACATATCGATAATTATC-3h) and orf6C-B (5h-AAGGATCCTTATTTGACTTCTGTAGCTAC-AA-3h) [8] , and the resulting amplicon was cloned into the expression vector at a unique BamHI restriction site. Competent Escherichia coli cells (JM109) were then transformed and selected on LB agar plates containing ampicillin (100 µg\ml). After selection and verification of positive clones by dideoxynucleotide DNA sequencing, the vector was transformed into the E. coli expression strain HMS174(DE3)pLysS. Transformed bacteria were propagated at 37 mC in LB broth containing ampicillin (100 µg\ml) and chloroamphenicol (35 µg\ml), and the expression was induced with 1 mM isopropyl β--thiogalactoside. Cultures were harvested after a 4 h post-induction incubation at 37 mC, and the recombinant enzyme was purified on a Ni-NTAagarose column as described previously [8] . Confirmation of SrtA ∆ N was achieved using a monoclonal antibody to the His ' tag (Sigma-Aldrich) and ion-trap MS on peptides recovered from ' in-gel ' tryptic digests of the recombinant protein.
Kinetic analysis of inhibitors Cbz-Leu-Pro-Ala-Thr-CHN 2 (I) and Cbz-Leu-Pro-Ala-Thr-CH 2 Cl (II)
Using methods described previously [8, 9] , SrtA ∆ N activity was measured with the internally quenched substrate 4- 
Affinity labelling of recombinant and wild-type SrtA with biotin-Ahx (aminohexanoyl)-Leu-Pro-Ala-Thr-CHN 2 (III)
For the detection and disclosure of SrtA ∆ N with biotin-Ahx-LeuPro-Ala-Thr-CHN # (III), crude lysates of transfected E. coli cells (freshly induced) were prepared, followed by purification of the recombinant enzyme on a Ni-NTA-agarose column as previously described [8] . For the disclosure of wild-type SrtA in S. aureus, a 50 ml overnight culture of the organism in LB broth was prepared. The bacterial cells were centrifuged at 3000 g for 15 min and the resulting pellet was washed in 5 ml of SrtA buffer. The washed bacteria were then resuspended in 1 ml of SrtA buffer containing 0.1 g of glass beads. The suspension was vortex-mixed continuously for 5 min followed by centrifugation at 1500 g for 15 min to remove the beads and unbroken cells. To 100 µl of purified SrtA ∆ N and the crude bacterial preparations, the inhibitor biotin-Ahx-Leu-Pro-Ala-Thr-CHN # (III) was added (final concentration 50 µM) before incubation at 37 mC for 30 min.
To detect the affinity-labelled recombinant and wild-type SrtA, samples were analysed by Western-blot analysis [15, [20] [21] [22] . Briefly, samples were treated with denaturing treatment buffer and the proteins separated by SDS\PAGE on 4 -20 % (w\v) linear gradient gels, followed by semi-dry transfer to a nitrocellulose membrane (Schleicher and Schu$ ll, Dassel, Germany). After transfer, non-specific binding sites were quenched with a 3 % (w\v) solution of BSA in 20 mM Tris\HCl (pH 7.4), containing 150 mM NaCl. To detect the biotin group, the membrane was incubated with a streptavidin-alkaline phosphatase conjugate (1 : 500). To confirm the identity of affinitylabelled recombinant and wild-type SrtA, the expressed protein and crude S. aureus extracts were respectively incubated with a rabbit antiserum (1 : 5000) raised against SrtA ∆ N . Bound antibody was detected with a goat anti-rabbit IgG alkaline phosphatase conjugate (1 : 20 000). All protein bands were revealed after incubation of the membranes with the substrates 5-bromo-4-chloroindol-3-yl phosphate and Nitro Blue Tetrazolium.
RESULTS AND DISCUSSION
In the present study, we synthesized three substrate-derived, active site-directed, irreversible inhibitors of SrtA ∆ N . The inhibitor sequences were based on the substrate recognition motif of the protease (-Leu-Pro-Xaa-Thr-Gly-) in which the scissile amide bond between threonine and glycine residues was replaced with a diazoketone (-COCHN # ) or chloromethyl ketone (-COCH # Cl) grouping. To facilitate synthesis, we choose to use a P # (X) alanine residue (nomenclature of Schechter and Berger [23] ) in our inhibitor sequence since this residue is the smallest of the chiral amino acids that does not possess a nucleophilic side chain and, therefore, does not require the use of protecting groups that could complicate the synthetic strategy. Both the peptidyl-diazomethane and peptidyl-chloromethane sequences were chosen on the basis of their recognized ability to alkylate the active-site thiol group of cysteine proteases [19, 24] . This is pertinent in the light of previous site-directed mutagenesis studies, which demonstrated that Cys")% is essential for the catalytic
Figure 3 Mechanism of inhibition by the substrate-derived peptidyldiazomethane (I) and peptidyl-chloromethane (II) SrtA ∆N inhibitors
In the scheme shown, the protease E catalyses the hydrolysis of the substrate S to the fluorescent product P. The reaction is characterized by the standard kinetic constants K m and k cat . In the presence of competing inhibitor I, the protease binds the inhibitor to form the Michaelis complex EI, with a binding affinity characterized by the inhibitor constant K i . The protease is then covalently modified to the inactivated complex E-I, with a first-order rate constant k i .
Figure 4 Inhibition of SrtA ∆N by Cbz-Leu-Pro-Ala-Thr-CH 2 Cl (II)
Plot of the reciprocal of the apparent second-order rate constant A for inactivation versus inhibitor concentration [I] . Hydrolysis of the internally quenched substrate Dabcyl-Gln-Ala-LeuPro-Glu-Thr-Gly-Glu-Glu-Edans was performed in the presence of five different concentrations (25, 50 , 100, 150 and 200 µM) of the active-site directed peptidyl-chloromethane inhibitor CbzLeu-Pro-Ala-Thr-CH 2 Cl (II). Data were fitted by non-linear regression analysis to the integrated rate equation [P] l P _ (1ke − k app t ). The P _ and k app values were determined and used to evaluate the apparent second-order rate constant A for inactivation of SrtA ∆N in the presence of substrate.
activity of SrtA, and that the thiol-directed reagents methanethiosulphonates and p-hydroxymercuric benzoic acid (pHMB) block the catalytic function of the enzyme [7, 8] .
Progress curves for SrtA ∆ N -catalysed hydrolysis of the internally quenched substrate Dabcyl-Gln-Ala-Leu-Pro-Glu-ThrGly-Glu-Glu-Edans in the presence of different concentrations of Cbz-Leu-Pro-Ala-Thr-CHN # (I) and Cbz-Leu-Pro-Ala-Thr-CH # Cl (II) typified the action of active site-directed irreversible inhibitors operating via the mechanism illustrated in Figure 3 [25, 26] . Data from the curves were fitted, using non-linear regression analysis [26] , to the integrated rate equation [P] l P _ (1ke −k app t ). This equation represents a first-order rate process for the formation of product P as a function of time, where k app is the apparent rate constant and P _ represents the concentration 
peptidyl-diazomethane (I) and peptidyl-chloromethane (II) inhibitors
Data from the progress curves for Srt ∆N -catalysed hydrolysis of the internally quenched substrate Dabcyl-Gln-Ala-Leu-Pro-Glu-Thr-Gly-Glu-Glu-Edans in the presence of five different concentrations of inhibitors I and II (25, 50, 100, 150 and 200 µM) were fitted by non-linear regression analysis to the integrated rate equation [P] l P _ (1ke − k app t ). The P _ and k app values were determined and used to evaluate the apparent second-order rate constant A for inactivation of Srt ∆N in the presence of substrate. The individual kinetic constants k i and K i were then evaluated from a plot of 1/A versus inhibitor concentration [I] , and the specificity constant for each inhibitor (k i /K i ) calculated. Values represent the meanspS.E.M. for four determinations. of product at a time approaching infinity. Using five different concentrations for each inhibitor (25, 50, 100, 150 and 200 µM), the values k app and P _ were determined and utilized to evaluate the apparent second-order rate constant A for the inactivation of SrtA ∆ N in the presence of the substrate [25] . The individual kinetic constants k i and K i were then evaluated for both inhibitors from a plot of 1\A versus inhibitor concentration [I] [25] , and the specificity constant k i \K i was calculated. Figure 4 shows the plot for inactivation of SrtA ∆ N by the peptidyl-chloromethane inhibitor Cbz-Leu-Pro-Ala-Thr-CH # Cl (II). All the kinetic constants determined for inhibitors I and II are given in Table 1 . The first point of interest was the observation that the peptidylchloromethane inhibitor (II) inactivates SrtA ∆ N by approx. 2-fold more rapidly than the analogous diazomethane sequence (I), as revealed by the specificity constants k i \K i l 5.3i10% and 2.2i10% M −" : min −" respectively. Both inhibitors I and II exhibited almost identical, sub-micromolar inhibitor constants K i l 2.2i10 −( and 2.1i10 −( M respectively. This implies high affinity of interaction between the common tetrapeptide motif of each inhibitor and the SrtA ∆ N enzyme. The greater effectiveness of the chloromethane inhibitor (II) can be attributed almost exclusively to the increased rate at which it covalently modifies SrtA ∆ N . Therefore the peptidyl-diazomethane (I) covalently modifies SrtA ∆ N with a first-order rate constant k i l 5.8i10 −$ min −" , whereas the peptidyl-chloromethane (II) covalently modifies the enzyme by approx. 2-fold more rapidly (k i l 1.1i10 −# min −" ). This observation fits the known relative chemical reactivity of the electrophilic groupings of both inhibitors towards thiol nucleophiles [24, 27] . The first-order rate constants observed are considerably smaller than those previously determined for the inactivation of cysteine proteases by active-site directed peptidyl-diazomethanes and peptidylchloromethanes. For example, the peptidyl-chloromethane inhibitor Cbz-Phe-Phe-CH # Cl alkylates the active-site cysteine residue of cathepsin B with k i l 12.5 min −" [27] . This is approx. 1000-fold greater than the irreversible modification of SrtA ∆ N by the peptidyl-chloromethane sequence (II).
We have previously demonstrated that biotinylated peptidyldiazomethanes can be used as affinity labels for the detection of cysteine proteases from diverse sources such as human breast cancer cells [20] , human synovial fluid [28] and a medium conditioned by parasites [21] . On this basis, we wished to evaluate the potential of a biotinylated inhibitor of SrtA for the detection of functionally active forms of SrtA-like species in Gram-positive organisms. Towards this end, we prepared the biotinylated inhibitor sequence biotin-Ahx-Leu-Pro-Ala-Thr-CHN # (III). The strategy underlying the design of III was based on two tenets. First, we chose to prepare the peptidyl-diazomethane (I) over the slightly more active chloromethane sequence (II), as the latter has potential to cause non-specific alkylation of biomolecules [24] . Secondly, we incorporated an aminohexanoic spacer group between the recognition motif of the inhibitor and the biotin moiety to maximize the interaction with streptavidin-alkaline phosphatase, which we routinely use for disclosure of affinitylabelled proteolytic species after SDS\PAGE and Western-blot analysis.
During initial Western-blotting experiments, biotin-Ahx-LeuPro-Ala-Thr-CHN # (III) (50 µM) was examined for its ability to disclose SrtA ∆ N in E. coli cells transfected with the SrtA gene from S. aureus (within the pET-3d expression vector ; see Figure 5A ). As shown in Figure 5 , lane 1 contained a crude lysate prepared from a freshly induced culture of the transfected E. coli cells, whereas lane 2 contained the ' flow-through ' from the Ni-NTA-agarose column used to purify the expressed His ' -tagged SrtA ∆ N . In lane 3, the bound fraction eluted from the column with 10 mM imidazole (purified SrtA ∆ N ) was also analysed. In both lanes 1 and 2, the intensely stained protein species with an apparent molecular mass of 22 kDa was the endogenous biotin carbonyl carrier protein (BCCP). This species was totally absent in the fraction selectively eluted from the Ni-NTA-agarose column ( Figure 5, lane 3) . The band with an apparent molecular mass of approx. 30 kDa, which was present in both the crude cell lysate ( Figure 5 , lane 1) and eluted fraction ( Figure 5, lane 3) , was His ' -tagged SrtA ∆ N . The identity of the affinity-labelled SrtA ∆ N band was confirmed with a monoclonal antibody to the His ' sequence and a rabbit antiserum raised against the recombinant enzyme (results not shown). The molecular mass determined for SrtA ∆ N by SDS\PAGE was in agreement with the previous reports of Ton-That et al. [8] . In lane 4, pre-treatment of the purified Srt ∆ N sample with the thiol-directed inhibitor pHMB, before ' probing ' with biotin-Ahx-Leu-Pro-Ala-Thr-CHN # (III), resulted in complete diminution of SrtA ∆ N labelling. As the enzyme contains only a single cysteine residue (Cys")%) essential for catalytic activity [8, 9] , we can confidently conclude that the binding of this biotinylated inhibitor to SrtA ∆ N is indeed active-site-directed.
We also performed Western-blotting experiments with biotinAhx-Leu-Pro-Ala-Thr-CHN # (III) to detect the presence of wildtype SrtA in crude cell lysates from S. aureus (Oxford strain ; see Figure 5B ). In the duplicate control lanes 1 and 2, which contained unprobed cell lysate, the BCCP protein (22 kDa) was again observed. In the duplicate lanes 3 and 4, which contained cell lysate ' probed ' with biotin-Ahx-Leu-Pro-Ala-Thr-CHN # (III), the BCCP protein was detected along with an additional protein of apparent molecular mass 24 kDa. This molecular mass was consistent with the predicted value for wild-type SrtA. That this protein band was indeed affinity-labelled SrtA was confirmed with an antiserum raised against the recombinant form of the protein (see Figure 5B ).
The discrete labelling of only recombinant and wild-type forms of SrtA in crude cell lysates prepared from transfected E. coli cells and S. aureus respectively provides convincing evidence for the selectivity of action of the biotin-Ahx-Leu-Pro-Ala-Thr-CHN # inhibitor. As expected, biotin-Ahx-Leu-Pro-Ala-Thr-CHN # (III) selectively disclosed wild-type SrtA, but not SrtB in crude S. aureus extracts. Two aspects explain the specificity of our affinity label for SrtA only. First, SrtA is a constitutively expressed protease in S. aureus, whereas SrtB expression is tightly regulated by the concentration of iron, which was not added to our culture media [11] . Secondly, the previous studies of Mazmanian et al. [11] demonstrated the exquisite specificity of SrtA and SrtB towards cognate synthetic peptides modelled on their respective sorting signals. When tested against internally quenched fluorescent peptides, SrtB was shown only to cleave peptides containing the -Asn-Pro-Gln-Thr Asn-sorting sequence, and not the -Leu-Pro-Xaa-Thr Gly-sequence recognized by SrtA. In contrast, SrtA displayed exactly the contrary specificity. Consequently, we would not have expected SrtB to be inhibited by our biotinylated affinity label, even under conditions where the enzyme was expressed.
In conclusion, this paper has reported on the first substratederived irreversible inhibitors of SrtA that might find application in delineating the role of this cysteine protease-transpeptidase in cell surface protein sorting and adherence of Gram-positive organisms.
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